Press Releases

BOSTON, June 27, 2023 /PRNewswire/ — AVEO Oncology, an LG Chem company, (“AVEO”), announced today that it has completed enrollment in the pivotal Phase 3 TiNivo-2 study in patients with advanced relapsed or refractory renal cell carcinoma (RCC) following prior immunotherapy exposure. The study is evaluating FOTIVDA® (tivozanib) in combination with OPDIVO® (nivolumab), Bristol Myers Squibb’s anti-PD-1 immunotherapy. FOTIVDA is […]

Download PDF AVEO to Become the U.S. Foundation for LG Chem Life Sciences’ Oncology Division SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) — LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide […]

Download PDF BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) — AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders (the “Special Meeting”) held today, AVEO stockholders approved the adoption of the Agreement and Plan of […]

Download PDF Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend that AVEO Stockholders Vote “FOR” the Transaction BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) — AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before […]

Download PDF Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Announced entering a definitive agreement under which LG Chem will acquire AVEO for $15.00 per share in an all-cash transaction with an implied equity value of $566 million on a fully diluted basis – BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), […]

Download PDF SEOUL, South Korea and CAMBRIDGE, Mass. and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) — LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) and AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that they have entered into a definitive agreement under which LG Chem will acquire AVEO […]

Download PDF BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that, as disclosed on uspto.gov, the United States Patent and Trademark Office (“USPTO”) has allowed U.S. Patent Application No. 17/720,619, titled “Use of Tivozanib to Treat […]

Download PDF BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that Michael Bailey, president and chief executive officer, will participate in a panel discussion at the Cantor Fitzgerald Oncology & HemOnc Conference. The panel titled […]

Download PDF BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of its senior management team are scheduled to participate in three investor conferences in September, including: 2022 Wells Fargo Healthcare Conference Date: […]

Download PDF – Total Q2 2022 Net Revenue of $25.3 million including $25.0 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q2 2022 FOTIVDA U.S. Net Product Revenue Growth of 24% Compared with Q1 2022 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100.0 million to $110.0 million – – Company Streamlines Planned R&D Spending and Lowers Guidance to $50.0 million from $60.0 million to $70.0 million – – Company to host conference call […]

Download PDF BOSTON, July 28, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 4, 2022, to discuss the financial results and provide […]

Download PDF – This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada – – AVEO Currently Manufacturing Ficlatuzumab Clinical Supply; Potential Phase 3 Registrational Clinical Trial in HPV Negative R/M HNSCC Expected in 1H 2023 – BOSTON, June 22, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: […]

Download PDF BOSTON, June 21, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines […]

Download PDF Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib Latest analysis of Phase 2 study show tivozanib demonstrated promising activity in nccRCC patients, a difficult to treat patient population […]

Download PDF BOSTON, May 18, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. eastern time. A live webcast of the fireside chat can be accessed by […]

Download PDF – Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million ofFOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q1 2022 FOTIVDA Prescriptions Increased by 25% Compared With Q4 2021 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million – – Company to Host Conference Call Today at 8:30 a.m. ET – BOSTON, May 05, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a […]

Download PDF BOSTON, April 28, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. AVEO’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, May 5, 2022, to discuss the financial results and provide […]

Download PDF – Total 2021 Net Revenue of $42.3 Million – – FOTIVDA® (tivozanib) U.S. Net Product Revenue of $38.9 Million since March 22, 2021 – – FOTIVDA U.S. Net Product Revenue of $16.8 Million for 4Q 2021, Driven by a 26% Increase in Prescriptions Filled Compared to 3Q 2021 – – Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million – – Long-term data from pivotal TIVO-3 study presented at ASCO GU […]

Download PDF BOSTON, March 07, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial results on Monday, March 14, 2022. AVEO’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, March 14, 2022, to discuss the financial results and provide […]

Download PDF – Actinium to apply its proprietary Antibody Warhead Enabling (AWE) technology platform to perform conjugation of AVEO’s ErbB3 targeted antibody with Actinium-225, a potent alpha-emitting radioisotope, to form a novel Ac-225 ErbB3 targeted radiotherapy– ErbB3, also known as HER3, is overexpressed in several solid tumor indications with high unmet needs, including colorectal, gastric, […]

Download PDF Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib) Long-term data from pivotal TIVO-3 study continue to demonstrate durable disease control and positive trend for overall survival for FOTIVDA® (tivozanib) Data Presented at the ASCO 2022 GU Cancers Symposium BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) — AVEO […]

Download PDF BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 9:20 a.m. eastern time. A live webcast of the fireside chat can be accessed by visiting […]

Download PDF First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for the DEDUCTIVE HCC study and the recently initiated Phase 1b/2 IMMCO-1 study of tivozanib and atezolizumab in multiple immunologically cold tumors BOSTON, Jan. 20, 2022 (GLOBE […]

Download PDF – Phase 2 Clinical Trial Targeted to Commence in 2022 – WILMINGTON, Del. & BOSTON–(BUSINESS WIRE)–Jan. 5, 2022– NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they […]

Download PDF Manufacturing of Ficlatuzumab Clinical Supply to Commence in 2Q 2022; Initiation of Registrational Study in HPV Negative R/M HNSCC Expected in 1H 2023 BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement with […]

Download PDF BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022. “I am proud of the entire AVEO team this year, as we accomplished several key milestones in the face of what remains a challenging environment with the ongoing COVID-19 pandemic,” said Michael […]

Download PDF BOSTON, Dec. 22, 2021 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10th to Thursday, January 13th. A webcast of the fireside chat with AVEO’s management team […]

Download PDF – Former chief operating officer of Enzyvant Therapeutics brings over 20 years of biotech leadership experience – BOSTON–(BUSINESS WIRE)–Dec. 1, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be responsible for overseeing operational functions key to maximizing the […]

Download PDF BOSTON–(BUSINESS WIRE)–Nov. 10, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, todayannounced that members of its senior management team will participate in two upcoming virtual investor conferences: Stifel 2021 Healthcare ConferenceDate: Monday, November 15Time: 1:20 p.m. Eastern Time 4th Annual Evercore ISI Healthconx ConferenceDate: Tuesday, November 30Time: 12:35 p.m. Eastern Time A webcast of the fireside chats, or […]

Download PDF – Total Q3 2021 Revenue of $15.2 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $14.3 Million –– Enrollment Open for Pivotal Phase 3 TiNivo-2 Clinical Trial of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) –– Ficlatuzumab and ERBITUX® (cetuximab) Granted Fast Track Designation by the U.S. FDA for R/R HNSCC; Potential Registrational Clinical Trial Expected to Commence in 1H 2023 –– Company to […]

Download PDF BOSTON–(BUSINESS WIRE)–Nov. 1, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, November 8, 2021, to discuss the financial results and provide a business […]

Download PDF BOSTON–(BUSINESS WIRE)–Sep. 20, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma (R/R HNSCC). Ficlatuzumab is AVEO’s investigational potent humanized immunoglobulin G1 […]

Download PDF BOSTON–(BUSINESS WIRE)–Aug. 30, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that members of its senior management team will participate in two upcoming virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment ConferenceDate: Monday, September 13Time: 7:00 a.m. Eastern Time Baird 2021 Global Healthcare ConferenceDate: Tuesday, September 14Time: 3:10 p.m. Eastern Time A live webcast of the Baird fireside chat can be accessed by […]

Download PDF – Total 2Q 2021 Revenue of $7.6 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $6.7 Million – – Pivotal Phase 3 TiNivo-2 Trial of FOTIVDA in Combination with OPDIVO® (nivolumab) on Track to Initiate Enrollment in 3Q 2021 – – COVID-19 Related Manufacturing Supply Shortages to Push Potential Registrational Study Start for Ficlatuzumab to 2023 – – Company to Host Conference […]

Download PDF BOSTON–(BUSINESS WIRE)–Jul. 29, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 5, 2021, to discuss the financial results and provide […]

Download PDF Webinar on Friday, July 16th at 12 p.m. Eastern Time FOTIVDA recently surpassed 300 total commercial prescriptions since its March 22, 2021 launch BOSTON–(BUSINESS WIRE)–Jul. 8, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) webinar focusing on FOTIVDA® (tivozanib), AVEO’s oral, once-daily, differentiated vascular endothelial […]

Download PDF Webinar on Wednesday, June 16 at 2:00 p.m. Eastern Time BOSTON–(BUSINESS WIRE)–Jun. 7, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader webinar focusing on ficlatuzumab, the Company’s investigational potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF), being studied […]

Download PDF BOSTON–(BUSINESS WIRE)–May 25, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will present at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the […]

Download PDF – Study Achieved Primary Endpoint of mPFS in Patients Treated with Ficlatuzumab/Cetuximab (ERBITUX®) Combination – – 38% ORR, Including 13% CRs and 25% PRs, and Median PFS of 4.1 months Observed in HPV Negative Patients Treated with Ficlatuzumab/Cetuximab Combination – – Phase 3 Go/No-Go Decision Expected After FDA Feedback – – Results to […]

Download PDF – Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS Relative to Sorafenib Continues to Improve with Longer Follow-up – – Analysis of TEAEs in TIVO-3 Study Shows Longer Time to Onset and Fewer Dose Reductions for TEAEs for Tivozanib Compared to Sorafenib – – Data to be […]

Download PDF – U.S. Commercial Launch Underway with Fully Deployed Sales Force Following FDA Approval of FOTIVDA® (tivozanib) on March 10, 2021 – – FOTIVDA Net Product Revenue of $1.1 Million from Initial Distributor Orders in the Last Week of Q1; All Distributors Have Placed Reorders for Q2 – – Entered Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb for […]

Download PDF BOSTON–(BUSINESS WIRE)–May 3, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report first quarter 2021 financial results on Monday, May 10, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 10, 2021, to discuss the financial results and provide […]

Download PDF BOSTON–(BUSINESS WIRE)–Apr. 16, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company’s Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck cancer, Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished Professor in Oncology and director […]

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 29, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) as a recommended regimen for subsequent therapy. The subsequent therapy category follows the first-line treatment regimen recommendations for patients with clear cell histology renal cell carcinoma (ccRCC). On March 10, […]

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 26, 2021– AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the full exercise by the underwriters of their option to purchase an additional 900,000 shares, at a price to the public of $8.00 per share. The aggregate gross proceeds […]

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 23, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per share. The gross proceeds to AVEO from the offering are expected to be $48.0 million before deducting underwriting discounts and commissions and offering […]

Download PDF – FOTIVDA is the First Therapy Approved for Adults with Relapsed or Refractory Advanced RCC Following Two or More Prior Systemic Therapies – – AVEO ACE Patient Support Program in Place to Assist with Access, Affordability, and Treatment Adherence – BOSTON–(BUSINESS WIRE)–Mar. 22, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that FOTIVDA® (tivozanib) is now commercially […]

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 22, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. All of the shares […]

Download PDF – FOTIVDA® (tivozanib) Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies; AVEO Plans to Make FOTIVDA Available to Patients in the U.S. by March 31, 2021 – – Entered Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb for Planned Pivotal Phase 3 TiNivo-2 Study of […]

Download PDF – AVEO Pipeline to Include Global Rights to Three Clinical-Stage and One Commercial-Stage Assets, Including Ficlatuzumab and AV-380 – BOSTON–(BUSINESS WIRE)–Mar. 15, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it will regain its rights to AV-203 outside of North America, its clinical-stage potent humanized IgG1 monoclonal antibody that targets ErbB3 (also known as HER3), following […]

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 12, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate FOTIVDA® (tivozanib) in combination with OPDIVO® (nivolumab), Bristol Myers Squibb’s anti-PD-1 therapy, in the pivotal Phase 3 TiNivo-2 trial in patients with advanced relapsed or refractory renal cell carcinoma […]

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 11, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates. This second tranche was made available in connection with the recent U.S. Food and Drug Administration (FDA) approval of FOTIVDA® (tivozanib). “With the additional $20 million now […]

Download PDF – FOTIVDA is the First Therapy Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies – – AVEO Plans to Make FOTIVDA Available to Patients in the U.S. by March 31, 2021 – – Company to Host Conference Call and Webcast today, March 10, 2021, at 6:00 PM ET – BOSTON–(BUSINESS […]

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 10, 2021– AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO’s commercial strategy and operations, including the commercialization of FOTIVDA® (tivozanib). FOTIVDA is AVEO’s differentiated oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved in the U.S. for the treatment of adult patients […]

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 2, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021. A replay of the pre-recorded presentation can be accessed on Tuesday, March 9, 2021 in the investors section of the Company’s website at www.aveooncology.com. A […]

Download PDF BOSTON–(BUSINESS WIRE)–Feb. 18, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:00 p.m. Eastern Time. A live webcast of the fireside chat can be accessed by visiting the investors section of the Company’s […]

Download PDF – Data Presented at the ASCO 2021 GU Cancers Symposium – –Sequencing Data Support Tivozanib is a Differentiated Selective VEGF TKI; Q-TWiST Quality of Life Measure Shows Significant Improvement for Tivozanib over Sorafenib – BOSTON, Mass.–(BUSINESS WIRE)–Feb. 11, 2021– AVEO Oncology (Nasdaq: AVEO) today announced the presentation of two analyses of the Company’s pivotal TIVO-3 […]

Download PDF – $20M Tranche Available on Approval of Tivozanib – BOSTON–(BUSINESS WIRE)–Jan. 20, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates, to be added to the current tranched, $35 million debt facility secured with Hercules in August 2020 through an amendment to the amended […]

Download PDF – Data Presented at the 2021 ASCO GI Cancers Symposium – BOSTON–(BUSINESS WIRE)–Jan. 15, 2021– AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO’s vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) drug candidate, in combination […]

Download PDF – Commercial Readiness Nearing Completion in Support of Potential Tivozanib U.S. Launch – – Updated IP Strategy Offers Potential for Tivozanib Patent Term Extension to November 2028 – – Corinne D. Epperly, MD, MPH, Appointed to Board of Directors – – Phase 2 Open Label Randomized Study of Ficlatuzumab in HNSCC Enrollment Complete; Plans to Announce Results and Phase 3 […]

Download PDF BOSTON–(BUSINESS WIRE)–Jan. 6, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences: H.C. Wainwright Virtual BioConnect ConferenceDate: Monday, January 11 – Thursday, January 14 B. Riley Virtual Oncology Investor ConferenceDate: Wednesday, January 20Time: 1:30 PM Eastern Time A replay of the pre-recorded H.C. Wainwright presentation can be […]

Download PDF BOSTON, Mass.–(BUSINESS WIRE)–Jan. 5, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 5:20 p.m. Eastern Time. Following the presentation, Mr. Bailey will be joined by other members of AVEO’s management team for a question-and-answer session. A live webcast of the […]

Download PDF BOSTON–(BUSINESS WIRE)–Nov. 10, 2020– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the […]

Download PDF – U.S. Commercial Launch Preparations Underway Supporting the Tivozanib PDUFA Target Action Date of March 31, 2021 – – Ficlatuzumab Worldwide Rights Regained; Final Results from Open Label Randomized Phase 2 HNSCC Study and Plans for Pivotal Program Expected in the Middle of 2021 – – AV-380 IND Submission Expected by Year-end; Phase 1 Clinical Study Planned for […]

Download PDF BOSTON & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Nov. 5, 2020– AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced that previously reported results from the Phase 1b/2 TiNivo study of oral (PO) tivozanib, AVEO’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, in combination with intravenous (IV) nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, […]

Download PDF BOSTON–(BUSINESS WIRE)–Oct. 19, 2020– AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AVEO’s sales force in anticipation of the potential approval and launch of tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment […]

Download PDF BOSTON–(BUSINESS WIRE)–Sep. 15, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIVO-3 is the Company’s pivotal Phase 3 trial comparing tivozanib, AVEO’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, to sorafenib in third […]

Download PDF Announces Decision to Fund Clinical Manufacture of Ficlatuzumab for Potential Phase 3 Study and Update to Biodesix Partnership  No Change to AVEO Cash Runway Guidance BOSTON–(BUSINESS WIRE)–Sep. 8, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody which binds to the […]

Download PDF BOSTON–(BUSINESS WIRE)–Sep. 3, 2020– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences: Baird 2020 Global Healthcare ConferenceDate: Thursday, September 10Time: 8:30 AM Eastern Time H.C. Wainwright 22nd Annual Global Investment ConferenceDate: Monday, September 14Time: 4:30 PM Eastern Time A live webcast of the events can be accessed by […]

Download PDF – NDA Filing Accepted by U.S. FDA for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma; Assigned PDUFA Target Action Date of March 31, 2021 – – Preparations Underway to Support Potential Commercial Launch of Tivozanib in the U.S.; New Debt and Equity Financings, Partnership Milestones Potentially Provide for Working Capital into 2022 – – […]

Download PDF BOSTON–(BUSINESS WIRE)–Aug. 10, 2020– AVEO Oncology (Nasdaq: AVEO) today announced the closing of a tranched, $35 million debt facility with Hercules Capital, Inc. (NYSE: HTGC) and its affiliates. The new facility has a maturity of 36 months, extendable up to 48 months, and an interest-only period of 12 months, extendable up to 30 months upon the achievement of performance […]

Download PDF BOSTON–(BUSINESS WIRE)–Aug. 5, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin). The milestone relates to acceptance by the Japanese Pharmaceuticals and Medical Devices Agency of an investigational new drug (IND) application for tivozanib in a non-oncology indication being developed by Kyowa Kirin. “This milestone […]

Download PDF BOSTON–(BUSINESS WIRE)–Jun. 19, 2020– AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includes the partial exercise by the underwriters of their option to purchase an additional 1,225,000 shares, at a price to the public of $5.25 per share. The aggregate gross proceeds […]

Download PDF BOSTON–(BUSINESS WIRE)–Jun. 16, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $5.25 per share. The gross proceeds to AVEO from the offering are expected to be approximately $44.6 million before deducting underwriting discounts and commissions and […]

Download PDF BOSTON–(BUSINESS WIRE)–Jun. 15, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of $40.0 million of shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional $6.0 million of shares of its common stock. All of the shares […]

Download PDF – Tivozanib assigned PDUFA target action date of March 31, 2021; FDA indicates that it does not currently plan to convene an ODAC – BOSTON–(BUSINESS WIRE)–Jun. 1, 2020– AVEO Oncology (NASDAQ: AVEO) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib, the Company’s next-generation vascular […]

Download PDF – Final OS Hazard Ratio Improves to 0.97 – – Company to Host Conference Call Today at 8:30 am Eastern Time – BOSTON–(BUSINESS WIRE)–May 29, 2020– AVEO Oncology (NASDAQ: AVEO) today announced the presentation of results from the final analysis of overall survival (OS) in its pivotal Phase 3 TIVO-3 trial comparing tivozanib, the Company’s next-generation vascular […]

Download PDF BOSTON–(BUSINESS WIRE)–May 29, 2020– AVEO Oncology (NASDAQ: AVEO) today announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with IMFINZI® (durvalumab), AstraZeneca’s (LSE/STO/NYSE: AZN) human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in patients with hepatocellular […]

Download PDF BOSTON–(BUSINESS WIRE)–May 27, 2020– AVEO Oncology (NASDAQ: AVEO) today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders, employees and communities, the location of its 2020 Annual Meeting […]

Download PDF BOSTON–(BUSINESS WIRE)–Apr. 30, 2020– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2020 and provided a business update. “Our recent submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for tivozanib as a treatment for relapsed or refractory renal cell carcinoma (R/R RCC) […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 29, 2020– AVEO Oncology (NASDAQ: AVEO) today announced that the final overall survival analysis from its pivotal Phase 3 TIVO-3 trial comparing tivozanib, AVEO’s vascular endothelial growth factor receptor tyrosine kinase inhibitor, to sorafenib in 3rd and 4th line renal cell carcinoma, will be presented at the upcoming American Society of Clinical Oncology (ASCO) […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 31, 2020– AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma (RCC). “NDA submission is a distinguishing […]

Download PDF CAMBRIDGE, Mass. & BOULDER, Colo.–(BUSINESS WIRE)–Mar. 27, 2020– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2019 and provided a business update. “The coming months will be an important period for AVEO, with filing of a New Drug Application (NDA) for tivozanib as a treatment for relapsed or refractory renal cell carcinoma (RCC) planned for […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 19, 2020– AVEO Oncology (NASDAQ: AVEO) today announced that it will effect a 1-for-10 reverse stock split of its common stock that will be effective as of 5:00 p.m. Eastern Time today, February 19, 2020. AVEO’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis when the market opens on Thursday, February 20, […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 12, 2020– AVEO Oncology (NASDAQ: AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in patients with advanced, inoperable hepatocellular carcinoma (HCC) in the British Journal of Cancer. The article, titled “A multicentre phase 1b/2 study of tivozanib […]

Download PDF – Data Presented at the 2020 ASCO GI Cancers Symposium – CAMBRIDGE, Mass. & BOULDER, Colo.–(BUSINESS WIRE)–Jan. 27, 2020– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with nab-paclitaxel and gemcitabine in patients with […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 6, 2020– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Erick Lucera as chief financial officer. Mr. Lucera will be responsible for managing all aspects of the Company’s financial and accounting functions. “It is a pleasure to welcome Erick to the AVEO team,” said Michael Bailey, president and chief executive officer of AVEO. “With […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 4, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology. TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®), the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), to sorafenib in 350 subjects […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 26, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2019 at 4:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 19, 2019– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical and life sciences industries. “It is a pleasure to welcome Scarlett to our Board of Directors,” said Michael Bailey, president and chief executive officer of AVEO. “Her […]

Download PDF – Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC – – Outcomes Favor Tivozanib in Patients Previously Treated With Checkpoint Inhibitors as Well as Two VEGFR-TKIs – – Data Featured in Oral Presentation at the 18th International Kidney Cancer Symposium – CAMBRIDGE, […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 12, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. “This quarter we have made meaningful progress toward our goal of bringing effective and better tolerated therapies to patients battling kidney and other cancers,” said Michael Bailey, president and chief executive officer of AVEO. […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 7, 2019– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML). AVEO will […]

Download PDF – NDA Filing Planned for 1Q20 for Relapsed/Refractory RCC – – Company Plans Final OS Analysis in 2Q20 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 4, 2019– AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 2019 overall survival (OS) analysis of the TIVO-3 trial and the […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 30, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with IMFINZI® (durvalumab), AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 26, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at 10:05 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of […]

Download PDF – Results Suggest Additive or Synergistic Activity in Both Treatment Naïve and Previously Treated Patients –    -Tivozanib-Nivolumab Combination Generally Well Tolerated –   – Data to be Presented at the ESMO 2019 Annual Congress –   CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 23, 2019– AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the upcoming presentation of final results from the […]

Download PDF – 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm – – Company Plans to Discuss Updated Results with FDA – – AVEO to Host Conference Call Today at 8:00 am Eastern Time – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 10, 2019– AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3 […]

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 8, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the second quarter ended June 30, 2019 and provided a business update. “As we move toward reporting more mature interim overall survival (OS) results from our TIVO-3 study of tivozanib in advanced kidney cancer, AVEO continues to make meaningful clinical, regulatory and strategic progress across our pipeline,” […]